Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-013359
Filing Date
2023-04-19
Accepted
2023-04-19 08:01:08
Documents
6
Period of Report
2023-05-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A labp_def_14a_4.19.23.htm DEF 14A 1199190
2 GRAPHIC img129399798_0.jpg GRAPHIC 37873
3 GRAPHIC img129399798_1.jpg GRAPHIC 3038
4 GRAPHIC img129399798_2.jpg GRAPHIC 3038
5 GRAPHIC img129399798_3.jpg GRAPHIC 576156
6 GRAPHIC img129399798_4.jpg GRAPHIC 188633
  Complete submission text file 0000950170-23-013359.txt   2310148
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

EIN.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39971 | Film No.: 23828486
SIC: 2834 Pharmaceutical Preparations